China Yct International Group (CYIG) Gross Profit Margin starting from the third quarter 2018 to third quarter 2017, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
China Yct International Group, Inc.  (CYIG)


China Yct International Group's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYIG Gross Profit Margin (Dec 31 2018)
Q3 		(Sep 30 2018)
Q2 		(Jun 30 2018)
Q1 		(Mar 31 2018)
Q4 		(Dec 31 2017)
Q3
Y / Y Revenue Change 13.27 %
Seq. Revenue Change 4.33 %
Revenue In Millions $19.49
Gross Profit Margin 45.24 %
Gross Profit Margin Total Ranking # 2309
Gross Profit In Millions $8.82
Y / Y Gross Profit Change 29.93 %
Seq. Gross Profit Change 9.36 %


Commenting Third Quarter 2018 Gross Profit Margin
China Yct International Group, Inc. Gross Profit grew by 9.36 % in Q3 sequentially to 9 millions, while Revenue increased by 4.33 %, this led to improvement in the company's Gross Profit Margin to 45.24 %, Gross Profit Margin remained below China Yct International Group, Inc. average.


Observing third quarter 2018 results within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 2309, from total ranking in the previous quarter at 2487.
Learn about Gross Margin
CYIG's Gross Profit Margin third quarter 2018 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 112
Healthcare Sector # 323
Overall # 2185

Gross Profit Margin Statistics
High Average Low
57.26 % 46.95 % 36.46 %
(Sep 30 2011)   (Sep 30 2017)


CYIG Gross Income Trends • More of CYIG's Profitabilty Ratios • CYIG Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
CYIG's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
CYIG's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for CYIG's Competitors
Gross Profit Margin Profit Margin for China Yct International Group's Suppliers
Gross Profit Margin Profit Margin for CYIG's Customers

You may also want to know
CYIG's Annual Growth Rates CYIG's Profitability Ratios CYIG's Asset Turnover Ratio CYIG's Dividend Growth
CYIG's Roe CYIG's Valuation Ratios CYIG's Financial Strength Ratios CYIG's Gross Profit Growth
CYIG's Roa CYIG's Inventory Turnover Ratio CYIG's Growth Rates CYIG's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2018, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2018 MRQ Gross ProfitDec 31 2018 MRQ Revenue
Sangui Biotech International Inc  99.94 %$ 0.044  Millions$ 0.044  Millions
Paratek Pharmaceuticals Inc   99.41 %$ 16.917  Millions$ 17.017  Millions
Cti Biopharma Corp   99.40 %$ 14.390  Millions$ 14.477  Millions
Omeros Corporation  99.29 %$ 21.860  Millions$ 22.017  Millions
Axim Biotechnologies Inc   99.19 %$ 0.166  Millions$ 0.167  Millions
Ionis Pharmaceuticals Inc   99.05 %$ 190.293  Millions$ 192.113  Millions
Achaogen, Inc.  99.01 %$ 2.005  Millions$ 2.025  Millions
Lexicon Pharmaceuticals Inc   98.55 %$ 16.824  Millions$ 17.071  Millions
Regeneron Pharmaceuticals Inc   98.26 %$ 1,894.245  Millions$ 1,927.797  Millions
Skinvisible Inc   98.19 %$ 0.013  Millions$ 0.013  Millions
Intercept Pharmaceuticals inc   98.11 %$ 52.273  Millions$ 53.280  Millions
Agios Pharmaceuticals Inc   97.66 %$ 29.311  Millions$ 30.013  Millions
Corcept Therapeutics Inc  97.64 %$ 65.252  Millions$ 66.831  Millions
Tetraphase Pharmaceuticals Inc  96.96 %$ 4.153  Millions$ 4.283  Millions
Ultragenyx Pharmaceutical Inc   96.88 %$ 15.754  Millions$ 16.261  Millions
Adamas Pharmaceuticals Inc  96.73 %$ 12.880  Millions$ 13.315  Millions
Intellipharmaceutics International Inc   96.47 %$ 0.374  Millions$ 0.388  Millions
Supernus Pharmaceuticals inc   96.39 %$ 111.746  Millions$ 115.934  Millions
Travere Therapeutics Inc   96.34 %$ 42.168  Millions$ 43.771  Millions
Ptc Therapeutics inc   96.21 %$ 82.577  Millions$ 85.833  Millions
Eli Lilly And Company  95.88 %$ 5,405.500  Millions$ 5,637.600  Millions
Celgene Corp  95.79 %$ 3,867.000  Millions$ 4,037.000  Millions
Ascendis Pharma A  95.38 %$ 11.851  Millions$ 12.424  Millions
Acadia Pharmaceuticals Inc   95.26 %$ 56.748  Millions$ 59.571  Millions
Oramed Pharmaceuticals Inc  94.81 %$ 0.639  Millions$ 0.674  Millions
Zyla Life Sciences  93.96 %$ 7.983  Millions$ 8.496  Millions
Siga Technologies Inc  93.44 %$ 1.466  Millions$ 1.569  Millions
Alkermes Plc   93.31 %$ 294.624  Millions$ 315.762  Millions
Jazz Pharmaceuticals Plc  92.56 %$ 440.997  Millions$ 476.457  Millions
Alnylam Pharmaceuticals Inc   92.08 %$ 19.368  Millions$ 21.033  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.